|LETTER TO THE EDITOR
|Year : 2017 | Volume
| Issue : 1 | Page : 42
Use of proton-pump inhibitors and risk of kidney failure: an alarming sign!
Uday V Mateti Pharm.D., Ph.D
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte University, Deralakatte, Mangalore, India
|Date of Submission||29-Sep-2016|
|Date of Acceptance||05-Apr-2017|
|Date of Web Publication||13-Jun-2017|
Uday V Mateti
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte University, Deralakatte, Mangalore
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Mateti UV. Use of proton-pump inhibitors and risk of kidney failure: an alarming sign!. J Egypt Soc Nephrol Transplant 2017;17:42
Proton-pump inhibitors (PPIs) are widely used prescription medications globally and are promoted as safe and accessible (without prescription) over the counter. These are commonly prescribed for the management of dyspepsia, peptic ulcers, Helicobacter pylori infection, and hospital-induced stress . Numerous studies have stated that extensive use of PPIs is outside the contemporary recommending guidelines. Numerous observational studies on the use of PPIs have reported unusual adverse drug reactions (ADRs) including hip fracture, community-acquired pneumonia, acute interstitial nephritis, and acute kidney injury ,,. It is presumable that use of PPIs could also be a risk factor for chronic renal failure (CRF), potentially arbitrated by persistent acute kidney injury ,. Nevertheless, growing evidence reveals that PPIs are associated with a number of ADRs and are overprescribed. The use of PPIs and risk of kidney injury reported by different studies are summarized in [Table 1]. It is time to investigate the relationship between CRF and PPI usage. The problem with previously conducted studies is that patients take more than one medication, and therefore the exact role of PPIs and their impact on the incidence of CRF is hard to determine. It requires extensive follow-up of patients and suitable controls.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J et al.
Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016; 176:238–246.
Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z et al.
Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016; 27:3153–3163.
Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX et al.
Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open 2015; 3:E166–E171.
Sampathkumar K, Ramalingam R, Prabakar A, Abraham A. Acute interstitial nephritis due to proton pump inhibitors. Indian J Nephrol 2013; 23:304–307.
] [Full text]
Klepser DG, Collier DS, Cochran GL, Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013; 14:150.